Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $10.2 million.

  • Fate Therapeutics' Other Non-Current Assets changed 0.0% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.2 million for FY2024, which is 3261.51% down from last year.
  • Per Fate Therapeutics' latest filing, its Other Non-Current Assets stood at $10.2 million for Q3 2025, which was down 0.0% from $10.2 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Other Non-Current Assets peaked at $15.2 million during Q1 2021, and registered a low of $10.2 million during Q3 2024.
  • Moreover, its 5-year median value for Other Non-Current Assets was $15.2 million (2023), whereas its average is $13.9 million.
  • In the last 5 years, Fate Therapeutics' Other Non-Current Assets changed by 0.0% in 2021 and then tumbled by 3261.51% in 2024.
  • Fate Therapeutics' Other Non-Current Assets (Quarter) stood at $15.2 million in 2021, then changed by 0.0% to $15.2 million in 2022, then dropped by 0.33% to $15.2 million in 2023, then tumbled by 32.62% to $10.2 million in 2024, then changed by 0.0% to $10.2 million in 2025.
  • Its Other Non-Current Assets was $10.2 million in Q3 2025, compared to $10.2 million in Q2 2025 and $10.2 million in Q1 2025.